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Abstract
Background: Neovascular glaucoma is a refractive glaucoma. Recently, anti-VEGF factors have been used alone or
in combination for the treatment of neovascular glaucoma. However, the medium- and long-term efficacy of such
drugs remains to be evaluated. This study was to determine the efficacy of intravitreal ranibizumab combined with
Ahmed glaucoma valve implantation for the treatment of neovascular glaucoma.
Methods: In this prospective non-randomized study, 43 neovascular glaucoma patients (43 eyes) were assigned to
receive either 0.5 mg intravitreal ranibizumab for three to 14 days before Ahmed glaucoma valve implantation
(injection group, n = 21) or Ahmed glaucoma valve implantation alone (control group, n = 22). The patients were
followed up for six to 12 months. Differences in surgical success rate, intraocular pressure, best corrected visual
acuity, anti-glaucoma medications and postoperative complications were compared between the two groups.
Surgical success was defined as IOP > = 6 mm Hg and < = 21 mm Hg, with or without the use of anti-glaucoma
medications, and without severe complications or reoperation.
Results: Of the 43 patients, 40 completed the 6-month follow-up and 37 completed the 1-year follow-up. Success
rate was 73.7 % vs. 71.4 % at six months and 72.2 % vs. 68.4 % at 12 months in the injection group and the control
group respectively. No significant difference was noted between the two groups (six months: P = 0.87, 12 months:
P = 1.00). There were no significant differences in the two groups with respect to intraocular pressure, best
corrected visual acuity, anti-glaucoma medications or postoperative complications at six months or 12 months.
Conclusions: Single intravitreal ranibizumab (0.5 mg) before surgery has no significant effect on the
medium- or long-term outcomes of neovascular glaucoma treated with Ahmed glaucoma valve
implantation.
Trial registration: Chinese Clinical Trial Registry (ChiCTR-OOC-14005709, Trial registration date: 2014-12-01)
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Background
Neovascular glaucoma (NVG) is a medical condition in
which neovascularization involving the iris and the an-
terior chamber angle is accompanied by the formation
of a fibrovascular membrane that results in secondary
angle closure and obstructs the aqueous outflow. The
main causes include diabetic retinopathy (DR), retinal
vein occlusion (RVO), retinal artery occlusion (RAO)
and ocular ischemic syndrome [1]. Ahmed glaucoma
valve (AGV) implantation is an effective treatment for
NVG, but the procedure is associated with poor out-
comes [2]. A study found that vascular endothelial
growth factor (VEGF) is a key factor causing NVG, as
demonstrated by significantly higher VEGF levels in the
aqueous humor of NVG patients [3]. VEGF levels in the
aqueous humor are known to play a significant role in
determining the outcomes of NVG patients after AGV
implantation [4].
Because of their role in inhibiting intraocular neovas-
cularization and mitigating damage to the blood ocular
barrier due to leakage from new vessels, anti-VEGF fac-
tors have been used alone or in combination for the
treatment of NVG. However, currently available evi-
dence remains insufficient to confirm the effectiveness
of such drugs. Ranibizumab (Lucentis) is now used in
the treatment of age-related macular degeneration and
macular edema as an anti-VEGF factor [5, 6], but it re-
mains unclear whether ranibizumab will affect the effi-
cacy of AGV implantation for NVG patients.
This prospective study was designed to compare the
difference in efficacy at a follow-up of six to 12 months
in NVG patients with or without a single intravitreal in-
jection of ranibizumab (IVR) before AGV implantation.
Methods
This study was a prospective, non-randomized, open-label,
controlled study. This study enrolled patients admitted to
the Department of Ophthalmology of Shanghai General
Hospital from December 2012 to March 2014. Inclusion
criteria were: 1) NVG patients (NVG was diagnosed by the
presence of active neovascularization in the iris and/or
angle, high intraocular pressure (IOP > 21 mm Hg, 1 mm
Hg = 0.133 kPa, Goldmann applanation tonometer) and
underlying ischemic retinal diseases); 2) IOP > 21 mm Hg,
with or without anti-glaucoma medications or panretinal
photocoagulation (PRP) before; 3) 18 to 85 years old; 4) pa-
tients who chose IVR before AGV implantation or AGV
implantation only should complete a follow-up of six to
12 months. Exclusion criteria were: 1) patients combined
with other types of glaucoma or other serious eye diseases;
2) patients who had received glaucoma surgery or other in-
traocular surgery in either eye; 3) patients who had re-
ceived intravitreal injection in either eye within three
months before surgery; 4) patients who failed to complete
the scheduled follow-ups for various reasons; 5) IOP mea-
surements were made inaccurate for various reasons; 6)
IOP decreased (<= 21 mm Hg) after IVR and/or PRP; 7)
cataract surgery or vitreous surgery was needed during the
primary surgery; 8) surgery or intravitreal injection was
required for both eyes; and 9) pregnant patients or patients
combined with other serious uncontrolled medical
diseases. This study was approved by the Ethics Committee
of Shanghai General Hospital (registration number:
2012 K061), and it was registered with the Chinese
Clinical Trial Registry (registration number: ChiCTR-
OOC-14005709). All patients signed an informed con-
sent before participation in this study.
Grouping method: NVG patients through preliminary
screening would be educated about IVR on its effect,
side-effect, risks, price and so on, then they chose to
accept IVR before AGV implantation (injection group)
or AGV implantation only (control group) at the discre-
tion of themselves and signed an informed consent.
Endpoints were: 1) completion of the scheduled
follow-up over the 6-month or 12-month period; 2) fail-
ure to be followed up as scheduled, being lost to follow
up, undergoing intraocular surgery including cyclopho-
tocoagulation during the follow-up period, or receiving
intravitreal injection during the follow-up period (col-
lectively referred to as dropouts).
We tried to do PRP for patients before IVR or AGV
implantation if possible, and evaluated again whether
they needed IVR or AGV implantation. As to those who
could not accept PRP due to very high IOP or corneal
edema pre-surgery, we applied this therapy just after
surgery (usually 1 or 2 weeks later). Patients would not
be enrolled if their IOPs were controlled by PRP before
AGV implantation (IOP < = 21 mm Hg).
IVR was performed three to 14 days prior to AGV im-
plantation. Under topical anesthesia, a needle was intro-
duced through the conjunctival surface 3.8 mm from the
corneal limbus in the affected eye for intravitreal injec-
tion of 0.5 mg/0.05 mL ranibizumab (Lucentis, 10 mg/mL;
Novartis, Basel, Switzerland). The puncture site was
pressed with a cotton swab for 5 to 10 s after the needle
was withdrawn. IOP and light perception were examined.
Sometimes anterior chamber paracentesis was performed
in patients with higher IOP. All patients were observed
more than three days. After that, AGV implantation
would be performed, once the IOPs of patients
reached 40 mm Hg during time, or it would be done
two weeks after IVR. Otherwise, Patients would not
be enrolled by the study if their IOPs were controlled
just by IVR (IOP < = 21 mm Hg).
AGV implantation was performed under peribulbar
anesthesia, a fornix-based conjunctival flap superior and
temporal to the affected eye was prepared until the
equator and a mitomycin C-soaked (0.4 mg/mL) cotton
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swab was applied to the area for two to five minutes be-
fore rinsing thoroughly with saline. An AGV (Model
FP7) drainage plate was fixed with 6–0 suture on the
surface of the sclera, with its anterior border 8 to
10 mm from the limbus. A 27G needle was introduced
into the interlamellar space of the sclera 5 mm behind
the limbus and pushed forward until into the anterior
chamber, where viscoelastic agent was injected while the
needle was being withdrawn slowly. A drainage tube was
implanted into the anterior chamber two to three mm
deep through the needle tract, and was mildly ligated
with 8–0 absorbable suture (6 to 7 mm behind the lim-
bus) before the conjunctival flap was tightly stitched. A
small amount of aqueous humor was drained through a
clear corneal if necessary incision to bring intraocular
pressure slightly higher than normal IOP. All the proce-
dures were completed by the authors.
Levofloxacin eye drops were applied at short intervals
before surgery. Tobramycin and dexamethasone ophthal-
mic solution was applied postoperatively once every two
hours for a total of three days, followed by four times a day
for two weeks. Tropicamide or atropine was administered
for two weeks for pupil dilation treatment where appropri-
ate. Some patients received panretinal photocoagulation
within one month after surgery. Anti-glaucoma medica-
tions were administered in light of IOP during follow-up.
The mean of three consecutive outpatient IOP mea-
surements just before surgery was used as the baseline
IOP. Patients were followed up on schedule (1–3d, 2w ±
1d, 1m ± 3d, 3m ± 5d, 6m ± 7d, 12m ± 14d) after surgery.
Best corrected visual acuity (BCVA) and IOP were deter-
mined and slit-lamp microscopy with a preset lens was
performed as a routine. Other tests including gonio-
scopy, ultrasound biomicroscopy, perimetry and retinal
nerve fiber layer scan were conducted in selected pa-
tients where appropriate. IOP, surgical success rate,
BCVA, anti-glaucoma medications and postoperative
complications were used as major outcome measures at
each follow-up time interval. Surgical success was de-
fined as IOP > = 6 mm Hg and < = 21 mm Hg, with or
without the use of anti-glaucoma medications, and with-
out severe complications or reoperation [7]. Surgical
failure was defined as IOP persistently < 6 mm Hg
or > 21 mm Hg for more than two weeks, or loss of
light perception, or the occurrence of any serious
complication including endophthalmitis, corneal de-
compensation, malignant glaucoma, severe choroidal
detachment (>180°), severe choroidal hemorrhage
(>180°), retinal detachment, ocular atrophy, or dis-
placement, withdrawal or exposure of drainage tube,
or necessity of reoperation for other reasons.
Statistical analysis was performed using statistical
package SAS9.13. Differences in gender and diagnoses at
baseline and postoperative complications, and dropout
rates during follow-up were compared between the two
groups using chi-square, corrected chi-square test or Fish-
er’s exact probability test. Differences in age, IOP, BCVA,
and medications at baseline and IOP decline, BCVA, and
medications during follow-up were compared using the
t test. Difference in success rates throughout follow-up
was compared using the Log-Rank test. P value < 0.05 was
considered statistically significant.
Results
A total of 43 patients (43 eyes) were enrolled. The pa-
tients were divided into the injection group (n = 21),
who received AGV implantation three to 14 days (aver-
age 8.6 ± 2.2 days) subsequent to IVR, and the control
group (n = 22), who received AGV implantation alone.
The baseline information of the two groups is presented
in Table 1. There were no significant differences in base-
line measures between the two groups.
Of the 43 patients, 40 completed the 6-month follow-
up and 37 completed the 1-year follow-up. In particular,
in the injection group two patients received intraocular
surgery (at three months and six months) and one pa-
tient was lost to follow up (at 12 months). In the control
group two patients received intraocular surgery (at six
months and 12 months) and one patient were lost to
follow up (at 12 months). The dropout rates were not
significantly different between the two groups (six
months: P = 0.52; 12 months: P = 0.95).
The mean IOPs at various time points throughout
follow-up decreased significantly from baseline in both
groups (ANOVA, α = 0.05). IOP rose gradually in both
groups with the passage of time. IOPs at various time
points throughout follow-up were not significantly dif-
ferent between the two groups (Table 2). The success
rates declined gradually in both groups with the passage
of time. Success rates at various time points throughout
follow-up (Table 3) were not significantly different be-
tween the two groups (P = 0.84, Fig. 1).
The two groups showed different patterns of BCVA
changes after surgery. In the injection group, BCVA im-
proved significantly and peaked for one to three months
before declining sharply to levels comparable to that of
the control group. In the control group, BCVA increased
slightly, peaked at one month, and then gradually de-
clined. Inter-group statistical analysis showed significant
differences only at three-month follow-up (Table 4).
BCVAs in both groups fell back to the baseline at six
months or 12 months.
The number of anti-glaucoma medications used at
various time points throughout follow-up in both groups
declined significantly from baseline (ANOVA, α = 0.05).
And the number of medications increased gradually in
both groups with the passage of time. There was no
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significant difference at various time points between the
two groups (Table 5).
Of the 21 patients in the injection group, anterior uve-
itis developed in seven patients one day after surgery,
but was resolved with topical steroid drops within two
weeks; proliferative membrane formed in the pupil in
one patient and was removed using YAG laser. Nine
patients experienced mild hyphema, which resolved it-
self within two weeks. Two patients developed mild
vitreous hemorrhage, which resolved itself within a
month. Two patients experienced transient ocular
hypertension (> = 30 mm Hg) and mild corneal edema
one day after surgery due to excessive viscoelastic res-
idues, which were alleviated after eyeball massage.
Blood clots developed in the drainage tube in three
patients, but resolved themselves in two and were
cured by YAG laser at day 3 after surgery. The lens
of the eye turned cloudy rapidly in one patient within
days after surgery, who underwent cataract surgery
two months after surgery and withdrew from this
study. Of the 23 patients in the control group, 10 pa-
tients developed postoperative anterior uveitis, which
was revolved within two weeks after topical steroid
drops. Nine patients experienced mild hyphema,
which resolved itself within two weeks. Five patients
developed mild vitreous hemorrhage, which resolved
itself within a month. Four patients experienced tran-
sient ocular hypertension (including two combined
with corneal edema), which were alleviated after eye-
ball massage. Blood clots developed in the drainage
tube in four patients, but resolved themselves. One
patient developed conjunctival retraction at three
months which did not cause drainage tube exposure
and therefore was left unattended. Mild choroidal
hemorrhage in local areas developed in one patient
one day after surgery as revealed by B ultrasonog-
raphy (less than 90°) and resolved itself gradually
within two months. No serious complications such as
malignant glaucoma, sustained low IOP, endophthal-
mitis, lose of light perception, and retinal detachment
occurred in either of the two groups (Table 6).
Discussion
Patients with early NVG have an open angle and normal
or slightly elevated IOP. Aggressive treatment with glau-
coma medications and laser therapy can bring the dis-
ease under control in some of these patients. However,
as the disease progresses, the angle is gradually closed
and IOP often continues to rise, leading to a poor re-
sponse to medications or laser, and surgery is usually
Table 1 Characteristics of patients with NVG
Injection Group Control Group P


















Prior intravitreal injection 0 0
NVI/NVA Degree 0.90
NVI only 3 2
NVI&NVA (Open-angle) 5 4
NVI&NVA (partial Closed-angle) 2 3















Note: The difference in gender was compared between the two groups using
the chi-square test, the difference in NVI/NVA degree was compared using
two-tailed Fisher’s exact test, and the differences in diagnosis and PRP before
were compared using the corrected chi-square test. Differences in age, IOP,
BCVA and anti-glaucoma medications were compared using the t test
Table 2 IOP (mm Hg) in both groups
Pre-surgery 2 weeks 1 month 3 months 6 months 12 months
Injection Group IOP (mean ± SD) 46.4 ± 13.3 14.5 ± 4.4 16.9 ± 4.2 18.1 ± 3.8 20.5 ± 4.5 21.1 ± 4.2
(Minimum - Maximum) (24.5–76.0) (6.5–24.0) (9.0–26.0) (10.0–24.0) (14.0–28.0) (15.5–28.0)
Control Group IOP (mean ± SD) 45.0 ± 14.9 15.6 ± 5.6 17.1 ± 5.3 19.4 ± 5.0 20.2 ± 3.9 22.1 ± 4.7
(Minimum - Maximum) (23.5–78.5) (6.0–27.5) (8.0–28.0) (12.0–31.5) (14.5–27.0) (12.0–30.0)
P 0.74 0.51 0.85 0.35 0.83 0.53
Note: IOPs before surgery and at two weeks, one month, three months, six months and 12 months after surgery were determined using an applanation tonometer
(mean of 9 am and 4 pm measurements). Differences in IOPs at various time points throughout follow-up were compared between the two groups using the t test
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required. AGV implantation is an effective method for
the treatment of NVG, especially for patients with angle
closure; however, NVG is associated with unfavorable
outcomes [2]. In this study, success was achieved in
71.4 % of the 22 patients in the control group at six
months and 68.4 % at 12 months. Some clinical studies
using the same surgical procedure have reached similar
results. For instance, Yalvac IS et al. [8] performed AGV
implantation alone in 38 patients with NVG and
achieved success in 63.2 % of the patients at one year.
Shen CC et al. [9] reported a success rate of 70 % and
60 % at one year and two years, respectively. In a retro-
spective study, Netland PA et al. [2] reported a success
rate of 73.1 % at one year, 61.9 % at two years, and only
20.6 % at five years, and considered NVG a high risk fac-
tor of AGV implantation failure.
The course of NVG depends on the occurrence and
development of new vessels in the iris and the anterior
chamber angle. Anti-VEGF factors can inhibit intraocu-
lar neovascularization, promote atrophy, and mitigate
damage to the blood-ocular barrier as a result of leakage
from new vessels. A study shows that ranibizumab can
lower IOP and alleviate rubeosis in patients with NVG
[10]. Therefore, anti-VEGF factors have been used alone
or in combination for the treatment of NVG. However,
currently available clinical evidence is inconclusive to es-
tablish the effectiveness of such drugs, especially in the
medium- and long-term [11, 12]. Our study examined
the efficacy of AGV implantation with or without a sin-
gle preoperative injection of 0.5 mg ranibizumab in pa-
tients with NVG. After a follow-up period of six months
to one year, the results showed that there was no signifi-
cant difference between the two groups in terms of IOP
control, success rate, or anti-glaucoma medications.
Currently available studies on glaucoma treatment
have reported the use of anti-VEGF factors under the
conjunctiva [13] and in the anterior chamber [7] and vit-
reous cavity [14–16], and even reported that topical eye
drops containing ranibizumab (2 mg/mL) after filtering
surgery can reduce the formation of bleb scarring [17].
However, there are large discrepancies in the conclu-
sions reached by a number of small-scale clinical studies
on NVG. Elmekawey H et al. [7] injected 0.5 mg ranibi-
zumab into the anterior chamber in 13 patients once
and two patients twice, and performed trabeculectomy
at four weeks when the new vessels resolved on the sur-
face of the iris. Success was achieved in 93.3 % of the pa-
tients at six months. Lüke J et al. [10] used repeated
intravitreal injections of ranibizumab for the treatment
of iris neovascularization (2.3 times/year) and neovascu-
lar glaucoma (3.6 times/year), in combination with trad-
itional therapies such as laser photocoagulation,
cryotherapy, and vitrectomy. This treatment approach
improved rubeosis and angle closure and achieved ef-
fective control of IOP. However, in a retrospective study,
Ma KT et al. [18] analyzed the outcomes of NVG patients
Table 3 Success rates of the two groups
2 weeks 1 month 3 months 6 months 12 months
Injection Group 95.2 % 90.5 % 80.0 % 73.7 % 72.2 %
(Successful subjects/total subjects) (20/21) (19/21) (16/20) (14/19) (13/18)
Control Group 90.9 % 81.8 % 77.3 % 71.4 % 68.4 %
(Successful subjects/total subjects) (20/22) (18/22) (17/22) (15/21) (13/19)
P 0.57 0.41 0.83 0.87 1.00
Note: Success was defined as IOP > = 6 mm Hg and < = 21 mm Hg, with or without the use of anti-glaucoma medications, and without severe complications or
reoperation. The differences in the success rates were compared between the two groups using the corrected chi-square test (two weeks, one month, and three
months) and chi-square test (six months) and two-tailed Fisher’s exact test (12 months)
Fig. 1 Success rates in both groups. Note: Difference in success rate throughout follow-up was compared between the two groups using the Log-Rank
test (P= 0.84)
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who received AGV implantation combined intraoperative
vitreous injection of 1.25 mg bevacizumab, and found that
its one-year success rate did not differ significantly from
AGV implantation alone. As our point of view, the pos-
sible reasons for the discrepancies of the above studies
may include different usages of anti-VEGF factors (espe-
cially single or repeated injections) and baseline differ-
ences in patients.
Intravitreal injection of anti-VEGF factors can help re-
duce macular edema and improve vision in patients with
RVO and DR [19–21]. Our data showed that early post-
operative BCVA improved from baseline in the two
groups, because IOP was brought under control and
corneal edema was alleviated in most patients. However,
with the extension of the follow-up period, BCVA gradually
declined, which may be caused by retinal deterioration and
worsened cataracts. In comparison, postoperative BCVA
improved more notably and this improvement lasted longer
in patients administered with ranibizumab (about three
months). The average BCVA in the injection group at three
months was higher than that in the control group, which is
positive for the quality of life and compliance of patients.
Nevertheless, the beneficial effect from ranibizumab disap-
peared thereafter and BCVA started to move closer be-
tween the two groups, with no significant difference in
medium- and long-term vision outcomes between the two
groups. Collectively, our results suggest that single IVR be-
fore surgery can only enhance vision in the early period
after surgery.
We observed that ranibizumab alleviated rubeosis in
patients and this effect started to appear two to three
days after administration as measured by slit lamp exam-
ination. However, there was no marked difference in the
incidence of postoperative complications between the
two groups. Early postoperative complications after
AGV implantation surgery for NVG included hyphema,
choroidal detachment, vitreous hemorrhage, and ob-
struction of drainage valves. The occurrence of these
complications was associated with a number of factors
such as the severity of neovascularization of the iris and
the anterior chamber angle, the severity of underlying
diseases, the level of baseline IOP, and changes in peri-
operative IOP (especially during surgery). For this rea-
son, we sought to achieve success in our first attempt
when preparing a scleral tunnel to avoid sharp IOP de-
cline as a result of repeated puncture of the anterior
chamber. Meanwhile an appropriate amount of visco-
elastic was injected into the anterior chamber to bring
IOP slightly higher than normal levels. The drainage
tube was partially ligated using absorbable suture. These
measures contribute to the maintenance of anterior
chamber and IOP during surgery and within a short
period after surgery. Therefore, no serious complications
occurred in early postoperative periods in both groups,
which, therefore, rendered the role of ranibizumab less
significant. Nakatake S et al. [22] studied a group of
NVG patients who had received trabeculectomy and also
found that the use of bevacizumab injections had no
notable effect on the incidence of preoperative complica-
tions such as hyphema and choroidal detachment. How-
ever, as ranibizumab was applied for a short time, our
study failed to establish a correlation between ranibizu-
mab and medium- and long-term complications after
AGV implantation, such as drainage valve exposure or
fiber encapsulation.
As a non-randomized study, anti-VEGF treatment was
assigned at the discretion of the subjects, and the sample
size was relative small, so bias would be inevitable be-
tween groups. To some extent, our study demonstrates
that single IVR before AGV implantation has no
Table 4 Best corrected visual acuities in both groups
Pre-surgery 2 weeks 1 month 3 months 6 months 12 months
Injection Group No. 27.4 ± 20.0 29.3 ± 16.0 39.2 ± 16.6 38.7 ± 16.0 29.7 ± 14.4 24.3 ± 11.1
LogMAR 1.1 ± 0.4 1.1 ± 0.3 0.9 ± 0.3 0.9 ± 0.3 1.1 ± 0.3 1.2 ± 0.2
Control Group No. 24.2 ± 19.5 28.7 ± 15.0 30.6 ± 15.6 28.0 ± 14.7 26.4 ± 13.6 22.1 ± 13.9
LogMAR 1.2 ± 0.4 1.1 ± 0.3 1.1 ± 0.3 1.1 ± 0.3 1.2 ± 0.3 1.2 ± 0.3
P 0.65 0.81 0.086 0.045 0.39 0.60
Note: Best corrected visual acuities (BCVAs) were determined by ETDRS digital letters before surgery, and two weeks, one month, three months, six months and
12 months after surgery. The differences in BCVAs at various time points throughout follow-up were compared between the two groups using the t test
Table 5 Glaucoma medications usage in both groups
Pre-surgery 2 weeks 1 month 3 months 6 months 12 months
Injection Group 2.5 ± 0.5 0.2 ± 0.4 0.6 ± 0.6 0.7 ± 0.6 1.0 ± 0.7 1.1 ± 0.8
Control Group 2.6 ± 0.5 0.2 ± 0.4 0.7 ± 0.7 0.7 ± 0.7 1.1 ± 0.8 1.3 ± 0.9
P 0.66 0.94 0.59 0.93 0.71 0.47
Note: The differences in the number of glaucoma medications used at various time points throughout follow-up were compared between the two groups using
the t test
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significant effect on the medium- and long-term out-
comes of NVG patients. As these drugs act in a very
time-dependant manner, it is necessary to carry out re-
peated injections to control the progression of the dis-
ease according to changes in rubeosis, IOP, BCVA or the
fundus during follow-up. Further studies are needed to
explore how to choose and evaluate clinical indicators
used to determine the timing of repeated administration.
However, we presume that the use of anti-VEGF factors
as needed may signal the direction of single or combined
treatment modalities for NVG in the future.
Conclusions
Single intravitreal ranibizumab (0.5 mg) before surgery
has no significant effect on the medium- or long-term
outcomes of neovascular glaucoma treated with Ahmed
glaucoma valve implantation.
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